Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-08
2008-07-08
McKane, Joseph (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S422000, C514S423000, C548S400000, C548S517000, C548S518000, C548S530000, C548S537000
Reexamination Certificate
active
10481882
ABSTRACT:
The invention relates to the use of structural analogues of distamycin having the general formula (I), (II), (III), (IV) or (V) or their pharmaceutically acceptable salts, for the preparation of a medicament for the therapeutic treatment of β-thalassaemia.
REFERENCES:
patent: 3432522 (1969-03-01), Preau
patent: 4738980 (1988-04-01), Arcamone et al.
patent: 4766142 (1988-08-01), Arcamone et al.
patent: 4912199 (1990-03-01), Lown et al.
patent: 5175182 (1992-12-01), Mongelli et al.
patent: 5272056 (1993-12-01), Burrows et al.
patent: 5446137 (1995-08-01), Maag et al.
patent: 6906103 (2005-06-01), Zhang et al.
patent: 7064218 (2006-06-01), Dyatkina et al.
patent: 94/25436 (1994-11-01), None
patent: 96/05196 (1996-02-01), None
patent: 98/21202 (1998-05-01), None
patent: WO 98 21202 (1998-05-01), None
N. Bianchi et al.; “Accumulation of gamma-globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustine”;British Journal of Haematology; vol. 113; No. 4; Jun. 2001; pp. 951-961.
N. Bianchi et al.; “The DNA-binding drugs mithramycin and chromomycin are powerful inducers of erythroid differentiation of human K562 cells”;British Journal of Haematology; vol. 104; No. 2; Feb. 1999; pp. 258-265.
R. D'Alessio et al.; “Structure-Activity Relationship of Novel Distamycin A Derivatives: Synthesis and Antitumor Activity”;Bioorganic&Medicinal Chemistry Letters; vol. 4; No. 12; 1994; pp. 1467-1472.
P. G. Baraldi et al.’ :DNA sequence—Recognizing properties of minor groove alkylating agents;Arzneimittel-Forschung; vol. 50; No. 3; Mar. 2000; pp. 309-315.
J. DeSimone, et al.; “5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons;”Proc. Natl. Acad. Sci. USA; vol. 79, pp. 4428-4431; Jul. 1982; Medical Sciences.
C. H. Lowrey, et al.; “Treatment with Azacitidine of Patients with End-Stage β-Thalassemia;”The New England Journal of Medicine; vol. 329, pp. 845-848; Sep. 16, 1993; No. 12.
S. P. Perrine, et al.; “A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the β-Globin Disorders;”The New England Journal of Medicine; vol. 328; pp. 81-86; Jan. 14, 1993; No. 2.
A. Al-Khatti, et al.; “Cooperative Enhancement of F-Cell Formation in Baboons Treated With Erythropoietin and Hydroxyurea;”Blood; vol. 72; pp. 817-819; No. 2 (August); 1988.
G. P. Rodgers, et al.; “Augmentation by Erythropoietin of the Fetal-Hemoglobin Response to Hydroxyurea in Sickle Cell Disease;”The New England Journal of Medicine; vol. 328; pp. 73-80; Jan. 14, 1993; No. 2.
G. P. Rodgers; “Novel Treatment Options in the Severe β-Globin Disorders;”British Journal of Haematology; vol. 91; pp. 263-268; 1995.
S. Torkelson, et al.; “Erythroid Progenitor Proliferation is Stimulated by Phenoxyacetic and Phenylalkyl Acids;”Blood Cells, Molecules, and Diseases; vol. 22; pp. 150-158; Jul. 31, 1996.
J. Rochette, et al.; “Fetal Hemoglobin Levels in Adults;”Blood Reviews; vol. 8; pp. 213-224; 1994.
N. Bianchi, et al.; “Induction of Erythroid Differentiation of Human K562 Cells by Cisplatin Analogs;”Biochemical Pharmacology; vol. 60; pp. 31-40; 2000.
N. Bianchi, et al.; “The DNA-binding drugs mithramycin and chromomycin are powerful inducers of erythroid differentiation of human K562 cells;”British Journal of Haematology; vol. 104; pp. 258-265; 1999.
S. Castaigne, et al.; “All-Trans Retinoic Acid as a Differentiation Therapy for Acute Promyelocytic Leukemia. I. Clinical Results;”Blood; vol. 76; No. 9; pp. 1704-1709; Nov. 1, 1990.
G. J. Dover, et al.; “Increased Fetal Hemoglobin in Patients Receiving Sodium 4-Phenylbutyrate;”The New England Journal of Medicine; vol. 327; No. 8; pp. 569-570; Aug. 20, 1992.
T. Ikuta, et al.; “Cellular and Molecular Effects of a Pulse Butyrate Regimen and New Inducers of Globin Gene Expression and Hematopoiesis;”Annals New York Academy of Sciences; vol. 850; pp. 87-99; 1998.
R. D'Alessio, et al.; “Structure-Activity Relationship of Novel Distamycin a Derivatives : Synthesis and Antitumor Activity;”Bioorganic&Medicinal Letters; vol. 4; No. 12; pp. 1467-1472; 1994.
P. G. Baraldi, et al.; “DNA Sequence-recognizing Properties of Minor Groove Alkylating Agents;”Arzneimittel-Forschung/Drug Research; vol. 50 (I); pp. 309-315; 2000.
W. Wang, et al.; “Anti-HIV-I Activity of Linked Lexitropsins;”J. Med. Chem.; vol. 35; pp. 2890-2897; 1992.
F. Osti, et al.; “Human Leukemia K562 Cells: Induction to Erythroid Differentiation by Guanine, Guanosine and Guanine Nucleotides;”Haematologica; vol. 82; pp. 395-401; 1997.
C. B. Lozzio, et al.; “Human Chronic Myelogenous Leukemia Cell-Line With Positive Philadelphia Chromosome;”Blood; vol. 45; No. 3; pp. 321-334; Mar. 1975.
R. Gambari, et al.; “Efficient cell proliferation and predominant accumulation of ε-globin mRNA in human leukemic K562 cells which produce mostly Hb Gower 1;”Experientia, vol. 41; pp. 673-675; 1985.
R. Gambari, et al.; “Human leukemia K-562 cells: induction of erythroid differentiation by 5-azacytidine;”Cell Differentiation; vol. 14; pp. 87-97; 1984.
T. R. Rutherford, et al.; “K562 human leukaemic cells synthesise embryonic haemoglobin in response to haemin;”Nature; vol. 280; pp. 164-165; Jul. 12, 1979.
J. Sambrook, et al., “Electrophoresis of RNA through Gels Containing Formaldehyde;”Extraction, Purification, and Analysis of Messenger RNA from Eukaryotic Cells; In: Molecular Cloning 2nded.; pp. 7.43-7.45; 1981.
E. Fibach; “Techniques for Studying Stimulation of Fetal Hemoglobin Production in Human Erythroid Cultures;”Hemoglobin, vol. 22 (5&6); pp. 445-458; 1998.
E. Fibach, et al.; “Hydroxyurea Increases Fetal Hemoglobin in Cultured Erythroid Cells Derived From Normal Individuals and Patients With Sickle Cell Anemia or β-Thalassemia;”Blood; vol. 81; No. 6; pp. 1630-1635; Mar. 15, 1993.
C. A. Heid, et al.; “Real Time Quantitative PCR;”Genome Research; vol. 6; pp. 986-994, 1996.
U. E. M. Gibson, et al.; “A Novel Method for Real Time Quantitative RT-PCR;”Genome Research; vol. 6, pp. 995-1001; 1996.
G. P. Rogers, et al; “Novel Treatment Options in the Severe β-Globin Disorders;”British Journal of Haematology; vol. 91; pp. 263-268 (1995).
Baraldi Pier Giovanni
Bianchi Nicoletta
Feriotto Giordana
Gambari Roberto
Mischiati Carlo
Associazione per La Lotta Alla Talassemia Di Ferrara
Associazione Veneta per La Lotta Alla Talassemia
Chung Susannah
Kratz Quintos & Hanson, LLP
McKane Joseph
LandOfFree
Heterocyclic and benzoheterocyclic polyamides structurally... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic and benzoheterocyclic polyamides structurally..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic and benzoheterocyclic polyamides structurally... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3926526